Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide Therapy for Alcohol Reduction (STAR)
NCT06015893Phase 2Active, not recruiting
- Sponsor
- National Institute on Drug Abuse
- Start
- Oct 2023
- Primary completion
- Mar 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alcohol use disorder (AUD) comparing Placebo with Semaglutide (2 arms). Primary endpoint: Drinks Per Week at 20 weeks. Started Oct 2023; status: active, not recruiting.
02
Drugs
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT06015893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06015893.